Edesa Biotech (EDSA) Change in Accured Expenses (2013 - 2025)

Edesa Biotech has reported Change in Accured Expenses for 13 years, with the latest figure at -$326452.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 1194.96% year-over-year to -$326452.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.1 million (down 1812.09% YoY) and the FY2025 annual result came in at -$715499.0, down 4167.65% from the prior year.
• Change in Accured Expenses eased to -$326452.0 in Q4 2025 per EDSA's latest filing, from $402422.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.6 million in Q1 2021 and troughed at -$3.6 million in Q2 2021.
• A 5-year average of -$7513.9 and a median of $154761.5 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2021 and 2025: Change in Accured Expenses jumped 3742.49% in 2021, then tumbled 1194.96% in 2025.
• Over 5 years, Change in Accured Expenses stood at $285825.0 in 2021, then plunged by 427.21% to -$935250.0 in 2022, then surged by 111.06% to $103456.0 in 2023, then sank by 71.18% to $29814.0 in 2024, then sank by 1194.96% to -$326452.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$326452.0, $402422.0, and -$261503.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.